<DOC>
	<DOCNO>NCT00739882</DOCNO>
	<brief_summary>To evaluate safety efficacy Raptiva ® compare placebo control chronic moderate severe plaque psoriasis involve hand and/or foot score Physician 's Global Assessment ( PGA - H &amp; F ) greater-than equal 3 subject suitable systemic therapy include cyclosporine , methotrexate , Psoralen-Ultraviolet Light A ( PUVA ) .</brief_summary>
	<brief_title>TRUST Study : Raptiva ® Hand &amp; Foot Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subject chronic ( disease history least 6 month diagnosis ) moderate severe plaque psoriasis involve hand and/or foot ( PGA H &amp; F rating 3 4 ) screening , fail respond , contraindication , intolerant systemic therapy include cyclosporin , methotrexate PUVA . Subjects outpatient . 2 . Stable disease study entry ( i.e . exacerbation psoriasis screen period ) . 3 . At least 18 year old . 4 . For woman childbearing potential , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study . For men , participation , mandatory practice birth control , exist data effect Raptiva ® spermatogenesis . 5 . Discontinuation systemic psoriasis treatment study entry . No washout period require traditional systemic psoriasis agent prior start study treatment . 6 . Discontinuation biological agent least 3 month prior first study injection . 7 . Discontinuation investigational drug treatment least 3 month prior SD 1 per washout requirement previous protocol . 8 . Willingness ability comply protocol requirement duration study . 9 . Written informed consent , give prior studyrelated procedure part normal medical care , understand subject may withdraw his/her consent time without prejudice future medical care . 1 . Hypersensitivity efalizumab excipients 2 . Current use prohibit therapy ( systemic topical treatment psoriasis , immunosuppressive drug , experimental drug , etc ) 3 . Previous current exposure Raptiva® 4 . History ongoing alcohol drug abuse 5 . History ongoing opportunistic infection ( e.g . systemic fungal infection , parasite ) serious infection . This include diagnosis require 2 week therapy , endocarditis osteomyelitis , treat past 6 month . In addition , subject currently receive antibiotic , antiviral , antifungal infection suppression prophylaxis diagnosis , subject exclude . 6 . Seropositivity hepatitis B antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) . Subjects undergo test screening , subject seropositive hepatitis B antigen , hepatitis C antibody , HIV exclude . 7 . History active latent tuberculosis within one year prior screening ( determine assessment accord national and/or local recommendation ) . 8 . Presence history malignancy , include lymphoproliferative disorder . 9 . Pregnancy breastfeed 10 . History hepatic cirrhosis , regardless cause severity 11 . History thrombocytopenia , haemolytic anaemia , clinically significant anaemia , white blood cell count &lt; 4,000 cells/μL &gt; 14,000 cells/μL , haematocrit ( HCT ) &lt; 30 % haemoglobin ( Hgb ) level &lt; 11 g/dL , platelet count &lt; 150,000 cells/μL 12 . Hepatic enzyme level ≥3 time upper limit normal serum creatinine level ≥2 time upper limit normal 13 . Vaccination live liveattenuated virus live liveattenuated bacteria vaccine within 14 day prior first dose Raptiva® 14 . Any medical condition , judgment Investigator , would jeopardise subject 's safety follow exposure investigational medicinal product ( Raptiva® placebo equivalent ) would significantly interfere Subject 's ability comply provision protocol . 15 . Other specific form psoriasis like guttate , erythrodermic pustular psoriasis sole predominant psoriasis . 16 . Immunodeficiencies .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Efalizumab ,</keyword>
	<keyword>Chronic plaque psoriasis</keyword>
	<keyword>moderate severe</keyword>
	<keyword>involve</keyword>
	<keyword>hand</keyword>
	<keyword>foot</keyword>
</DOC>